| 2026-04-29 |
财报披露：
美东时间 2026-04-29 盘前发布财报
|
| 2026-03-10 |
股东大会：
将于2026-04-09召开股东大会
会议内容 ▼▲
- 1.To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2025.
2.To confirm the 2025 interim dividends.
3.To appoint KPMG LLP as Auditor.
4.To authorise the Directors to agree the remuneration of the Auditor.
5.To re-elect Directors.
6.To approve the annual statement of the Chair of the Remuneration Committee and the Annual Report on Remuneration for the year ended 31 December 2025.
7.To renew the authorisation to grant awards under the French Appendix 3 of the AstraZeneca Performance Share Plan 2020.
8.To authorise limited political donations.
9.To authorise the Directors to allot shares.
10.To authorise the Directors to disapply pre-emption rights.
11.To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments.
12.To authorise the Company to purchase its own shares.
13.To reduce the notice period for general meetings.
|
| 2026-03-10 |
股东大会：
将于2026-04-09召开股东大会
会议内容 ▼▲
- 1.To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2025.
2.To confirm the 2025 interim dividends.
3.To appoint KPMG LLP as Auditor.
4.To authorise the Directors to agree the remuneration of the Auditor.
5.To re-elect Directors.
6.To approve the annual statement of the Chair of the Remuneration Committee and the Annual Report on Remuneration for the year ended 31 December 2025.
7.To renew the authorisation to grant awards under the French Appendix 3 of the AstraZeneca Performance Share Plan 2020.
8.To authorise limited political donations.
9.To authorise the Directors to allot shares.
10.To authorise the Directors to disapply pre-emption rights.
11.To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments.
12.To authorise the Company to purchase its own shares.
13.To reduce the notice period for general meetings.
|
| 2026-03-10 |
股东大会：
将于2026-04-09召开股东大会
会议内容 ▼▲
- 1.To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2025.
2.To confirm the 2025 interim dividends.
3.To appoint KPMG LLP as Auditor.
4.To authorise the Directors to agree the remuneration of the Auditor.
5.To re-elect Directors.
6.To approve the annual statement of the Chair of the Remuneration Committee and the Annual Report on Remuneration for the year ended 31 December 2025.
7.To renew the authorisation to grant awards under the French Appendix 3 of the AstraZeneca Performance Share Plan 2020.
8.To authorise limited political donations.
9.To authorise the Directors to allot shares.
10.To authorise the Directors to disapply pre-emption rights.
11.To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments.
12.To authorise the Company to purchase its own shares.
13.To reduce the notice period for general meetings.
|
| 2026-03-02 |
详情>>
股本变动：
变动后总股本155096.67万股
|
| 2026-02-24 |
详情>>
业绩披露：
2025年年报每股收益6.60美元,归母净利润102.25亿美元,同比去年增长45.34%
|
| 2025-11-06 |
详情>>
业绩披露：
2025年三季报(累计)每股收益5.10美元,归母净利润78.99亿美元,同比去年增长42.71%
|
| 2025-07-29 |
详情>>
业绩披露：
2025年中报每股收益3.46美元,归母净利润53.66亿美元,同比去年增长30.69%
|
| 2025-04-29 |
详情>>
业绩披露：
2025年一季报每股收益1.88美元,归母净利润29.16亿美元,同比去年增长33.82%
|
| 2025-02-18 |
股东大会：
将于2025-04-11召开股东大会
会议内容 ▼▲
- 1.To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2024;
2.To confirm the 2024 interim dividends;
3.To re-appoint PricewaterhouseCoopers LLP as Auditor;
4.To authorise the Directors to agree the remuneration of the Auditor;
5.To elect or re-elect Directors;
6.To approve the annual statement of the Chair of the Remuneration Committee and the Annual Report on Remuneration for the year ended 31 December 2024;
7.To authorise limited political donations;
8.To authorise the Directors to allot shares;
9.To authorise the Directors to disapply pre-emption rights;
10.To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments;
11.To authorise the Company to purchase its own shares;
12.To reduce the notice period for general meetings.
|
| 2025-02-18 |
股东大会：
将于2025-04-11召开股东大会
会议内容 ▼▲
- 1.To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2024;
2.To confirm the 2024 interim dividends;
3.To re-appoint PricewaterhouseCoopers LLP as Auditor;
4.To authorise the Directors to agree the remuneration of the Auditor;
5.To elect or re-elect Directors;
6.To approve the annual statement of the Chair of the Remuneration Committee and the Annual Report on Remuneration for the year ended 31 December 2024;
7.To authorise limited political donations;
8.To authorise the Directors to allot shares;
9.To authorise the Directors to disapply pre-emption rights;
10.To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments;
11.To authorise the Company to purchase its own shares;
12.To reduce the notice period for general meetings.
|
| 2025-02-18 |
股东大会：
将于2025-04-11召开股东大会
会议内容 ▼▲
- 1.To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2024;
2.To confirm the 2024 interim dividends;
3.To re-appoint PricewaterhouseCoopers LLP as Auditor;
4.To authorise the Directors to agree the remuneration of the Auditor;
5.To elect or re-elect Directors;
6.To approve the annual statement of the Chair of the Remuneration Committee and the Annual Report on Remuneration for the year ended 31 December 2024;
7.To authorise limited political donations;
8.To authorise the Directors to allot shares;
9.To authorise the Directors to disapply pre-emption rights;
10.To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments;
11.To authorise the Company to purchase its own shares;
12.To reduce the notice period for general meetings.
|
| 2025-02-18 |
详情>>
业绩披露：
2022年年报每股收益2.12美元,归母净利润32.88亿美元,同比去年增长2835.71%
|
| 2025-02-18 |
详情>>
业绩披露：
2024年年报每股收益4.54美元,归母净利润70.35亿美元,同比去年增长18.14%
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益3.57美元,归母净利润55.35亿美元,同比去年增长10.81%
|
| 2024-07-25 |
详情>>
业绩披露：
2024年中报每股收益2.65美元,归母净利润41.06亿美元,同比去年增长13.39%
|
| 2024-04-25 |
详情>>
业绩披露：
2024年一季报每股收益1.41美元,归母净利润21.79亿美元,同比去年增长20.85%
|
| 2024-03-07 |
股东大会：
将于2024-04-11召开股东大会
会议内容 ▼▲
- 1.To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2023.
2.To confirm the 2023 interim dividends.
3.To re-appoint PricewaterhouseCoopers LLP as Auditor.
4.To authorise the Directors to agree the remuneration of the Auditor.
5.To elect or re-elect Directors.
6.To approve the annual statement of the Chair of the Remuneration Committee and the Annual Report on Remuneration for the year ended 31 December 2023.
7.To approve the Directors' Remuneration Policy.
8.To approve amendments to the AstraZeneca Performance Share Plan 2020.
9.To authorise limited political donations.
10.To authorise the Directors to allot shares.
11.To authorise the Directors to disapply pre-emption rights.
12.To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments.
13.To authorise the Company to purchase its own shares.
14.To reduce the notice period for general meetings.
|
| 2024-03-07 |
股东大会：
将于2024-04-11召开股东大会
会议内容 ▼▲
- 1.To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2023.
2.To confirm the 2023 interim dividends.
3.To re-appoint PricewaterhouseCoopers LLP as Auditor.
4.To authorise the Directors to agree the remuneration of the Auditor.
5.To elect or re-elect Directors.
6.To approve the annual statement of the Chair of the Remuneration Committee and the Annual Report on Remuneration for the year ended 31 December 2023.
7.To approve the Directors' Remuneration Policy.
8.To approve amendments to the AstraZeneca Performance Share Plan 2020.
9.To authorise limited political donations.
10.To authorise the Directors to allot shares.
11.To authorise the Directors to disapply pre-emption rights.
12.To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments.
13.To authorise the Company to purchase its own shares.
14.To reduce the notice period for general meetings.
|
| 2024-03-07 |
股东大会：
将于2024-04-11召开股东大会
会议内容 ▼▲
- 1.To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2023.
2.To confirm the 2023 interim dividends.
3.To re-appoint PricewaterhouseCoopers LLP as Auditor.
4.To authorise the Directors to agree the remuneration of the Auditor.
5.To elect or re-elect Directors.
6.To approve the annual statement of the Chair of the Remuneration Committee and the Annual Report on Remuneration for the year ended 31 December 2023.
7.To approve the Directors' Remuneration Policy.
8.To approve amendments to the AstraZeneca Performance Share Plan 2020.
9.To authorise limited political donations.
10.To authorise the Directors to allot shares.
11.To authorise the Directors to disapply pre-emption rights.
12.To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments.
13.To authorise the Company to purchase its own shares.
14.To reduce the notice period for general meetings.
|
| 2024-02-20 |
详情>>
业绩披露：
2023年年报每股收益3.84美元,归母净利润59.55亿美元,同比去年增长81.11%
|
| 2023-03-22 |
股东大会：
将于2023-04-27召开股东大会
会议内容 ▼▲
- 1.To receive the Company’s Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2022.
2.To confirm dividends.
3.To reappoint PricewaterhouseCoopers LLP as Auditor.
4.To authorise the Directors to agree the remuneration of the Auditor.
5.To elect or re-elect Directors.
6.To approve the Annual Report on Remuneration for the year ended 31 December 2022.
7.To authorise limited political donations.
8.To authorise the Directors to allot shares.
9.To authorise the Directors to disapply pre-emption rights.
10.To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments.
11.To authorise the Company to purchase its own shares.
12.To reduce the notice period for general meetings.
13.To adopt new Articles of Association of the Company.
|
| 2023-03-22 |
股东大会：
将于2023-04-27召开股东大会
会议内容 ▼▲
- 1.To receive the Company’s Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2022.
2.To confirm dividends.
3.To reappoint PricewaterhouseCoopers LLP as Auditor.
4.To authorise the Directors to agree the remuneration of the Auditor.
5.To elect or re-elect Directors.
6.To approve the Annual Report on Remuneration for the year ended 31 December 2022.
7.To authorise limited political donations.
8.To authorise the Directors to allot shares.
9.To authorise the Directors to disapply pre-emption rights.
10.To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments.
11.To authorise the Company to purchase its own shares.
12.To reduce the notice period for general meetings.
13.To adopt new Articles of Association of the Company.
|
| 2023-03-22 |
股东大会：
将于2023-04-27召开股东大会
会议内容 ▼▲
- 1.To receive the Company’s Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2022.
2.To confirm dividends.
3.To reappoint PricewaterhouseCoopers LLP as Auditor.
4.To authorise the Directors to agree the remuneration of the Auditor.
5.To elect or re-elect Directors.
6.To approve the Annual Report on Remuneration for the year ended 31 December 2022.
7.To authorise limited political donations.
8.To authorise the Directors to allot shares.
9.To authorise the Directors to disapply pre-emption rights.
10.To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments.
11.To authorise the Company to purchase its own shares.
12.To reduce the notice period for general meetings.
13.To adopt new Articles of Association of the Company.
|
| 2022-03-23 |
股东大会：
将于2022-04-29召开股东大会
会议内容 ▼▲
- 1.To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2021
2.To confirm dividends
3.To reappoint PricewaterhouseCoopers LLP as Auditor
4.To authorise the Directors to agree the remuneration of the Auditor
5.To elect or re-elect Directors
6.To approve the Annual Report on Remuneration for the year ended 31 December 2021
7.To authorise limited political donations
8.To authorise the Directors to allot shares
9.To authorise the Directors to disapply pre-emption rights
10.To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments
11.To authorise the Company to purchase its own shares
12.To reduce the notice period for general meetings
13.To extend the AstraZeneca 2012 Savings Related Share Option Scheme
|
| 2022-03-23 |
股东大会：
将于2022-04-29召开股东大会
会议内容 ▼▲
- 1.To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2021
2.To confirm dividends
3.To reappoint PricewaterhouseCoopers LLP as Auditor
4.To authorise the Directors to agree the remuneration of the Auditor
5.To elect or re-elect Directors
6.To approve the Annual Report on Remuneration for the year ended 31 December 2021
7.To authorise limited political donations
8.To authorise the Directors to allot shares
9.To authorise the Directors to disapply pre-emption rights
10.To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments
11.To authorise the Company to purchase its own shares
12.To reduce the notice period for general meetings
13.To extend the AstraZeneca 2012 Savings Related Share Option Scheme
|
| 2022-03-23 |
股东大会：
将于2022-04-29召开股东大会
会议内容 ▼▲
- 1.To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2021
2.To confirm dividends
3.To reappoint PricewaterhouseCoopers LLP as Auditor
4.To authorise the Directors to agree the remuneration of the Auditor
5.To elect or re-elect Directors
6.To approve the Annual Report on Remuneration for the year ended 31 December 2021
7.To authorise limited political donations
8.To authorise the Directors to allot shares
9.To authorise the Directors to disapply pre-emption rights
10.To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments
11.To authorise the Company to purchase its own shares
12.To reduce the notice period for general meetings
13.To extend the AstraZeneca 2012 Savings Related Share Option Scheme
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-12 |
股东大会：
将于2021-05-11召开股东大会
会议内容 ▼▲
- 1.To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2020
2.To confirm dividends
3.To reappoint PricewaterhouseCoopers LLP as Auditor
4.To authorise the Directors to agree the remuneration of the Auditor
5.To elect or re-elect Directors
6.To approve the Annual Report on Remuneration for the year ended 31 December 2020
7.To approve the Directors' Remuneration Policy
8.To authorise limited political donations
9.To authorise the Directors to allot shares
10.To authorise the Directors to disapply pre-emption rights
11.To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments
12. To authorise the Company to purchase its own shares
13.To reduce the notice period for general meetings
14.To amend the rules of the Performance Share Plan 2020
|
| 2021-04-12 |
股东大会：
将于2021-05-11召开股东大会
会议内容 ▼▲
- 1.To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2020
2.To confirm dividends
3.To reappoint PricewaterhouseCoopers LLP as Auditor
4.To authorise the Directors to agree the remuneration of the Auditor
5.To elect or re-elect Directors
6.To approve the Annual Report on Remuneration for the year ended 31 December 2020
7.To approve the Directors' Remuneration Policy
8.To authorise limited political donations
9.To authorise the Directors to allot shares
10.To authorise the Directors to disapply pre-emption rights
11.To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments
12. To authorise the Company to purchase its own shares
13.To reduce the notice period for general meetings
14.To amend the rules of the Performance Share Plan 2020
|
| 2021-04-12 |
股东大会：
将于2021-05-11召开股东大会
会议内容 ▼▲
- 1.To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2020
2.To confirm dividends
3.To reappoint PricewaterhouseCoopers LLP as Auditor
4.To authorise the Directors to agree the remuneration of the Auditor
5.To elect or re-elect Directors
6.To approve the Annual Report on Remuneration for the year ended 31 December 2020
7.To approve the Directors' Remuneration Policy
8.To authorise limited political donations
9.To authorise the Directors to allot shares
10.To authorise the Directors to disapply pre-emption rights
11.To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments
12. To authorise the Company to purchase its own shares
13.To reduce the notice period for general meetings
14.To amend the rules of the Performance Share Plan 2020
|
| 2021-03-30 |
股东大会：
将于2021-04-30召开股东大会
|
| 2021-03-30 |
股东大会：
将于2021-04-30召开股东大会
|
| 2021-03-30 |
股东大会：
将于2021-04-30召开股东大会
|
| 2020-04-17 |
股东大会：
将于2020-04-29召开股东大会
|
| 2020-04-17 |
股东大会：
将于2020-04-29召开股东大会
|
| 2020-04-17 |
股东大会：
将于2020-04-29召开股东大会
|
| 2020-02-14 |
除权日：
美东时间 2020-02-27 每股派息0.95美元
|
| 2019-10-28 |
复牌提示：
2019-10-28 11:21:25 停牌，复牌日期 2019-10-28 12:02:54
|
| 2019-07-25 |
除权日：
美东时间 2019-08-08 每股派息0.44美元
|
| 2019-03-14 |
股东大会：
将于2019-04-26召开股东大会
|
| 2019-03-14 |
股东大会：
将于2019-04-26召开股东大会
|
| 2019-03-14 |
股东大会：
将于2019-04-26召开股东大会
|
| 2019-02-14 |
除权日：
美东时间 2019-02-28 每股派息0.95美元
|
| 2018-07-26 |
除权日：
美东时间 2018-08-09 每股派息0.44美元
|
| 2018-04-13 |
股东大会：
将于2018-05-18召开股东大会
会议内容 ▼▲
- 1.To receive the Company’s Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2017.
2.To confirm the first interim dividend of US$0.90 (68.9 pence, SEK 7.40) per ordinary share and to confirm, as the final dividend for 2017, the second interim dividend of US$1.90 (133.6 pence, SEK 14.97) per ordinary share.
3.To reappoint PricewaterhouseCoopers LLP as Auditor of the Company until the end of the next meeting at which accounts are laid before the Company.
4.To authorise the Directors to agree the remuneration of the Auditor.
5.To elect or re-elect the following Directors of the Company with effect from the end of the AGM as separate resolutions:
|
| 2018-04-13 |
股东大会：
将于2018-05-18召开股东大会
会议内容 ▼▲
- 1.To receive the Company’s Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2017.
2.To confirm the first interim dividend of US$0.90 (68.9 pence, SEK 7.40) per ordinary share and to confirm, as the final dividend for 2017, the second interim dividend of US$1.90 (133.6 pence, SEK 14.97) per ordinary share.
3.To reappoint PricewaterhouseCoopers LLP as Auditor of the Company until the end of the next meeting at which accounts are laid before the Company.
4.To authorise the Directors to agree the remuneration of the Auditor.
5.To elect or re-elect the following Directors of the Company with effect from the end of the AGM as separate resolutions:
|
| 2018-04-13 |
股东大会：
将于2018-05-18召开股东大会
会议内容 ▼▲
- 1.To receive the Company’s Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2017.
2.To confirm the first interim dividend of US$0.90 (68.9 pence, SEK 7.40) per ordinary share and to confirm, as the final dividend for 2017, the second interim dividend of US$1.90 (133.6 pence, SEK 14.97) per ordinary share.
3.To reappoint PricewaterhouseCoopers LLP as Auditor of the Company until the end of the next meeting at which accounts are laid before the Company.
4.To authorise the Directors to agree the remuneration of the Auditor.
5.To elect or re-elect the following Directors of the Company with effect from the end of the AGM as separate resolutions:
|
| 2018-02-02 |
除权日：
美东时间 2018-02-15 每股派息0.95美元
|
| 2017-07-28 |
除权日：
美东时间 2017-08-09 每股派息0.44美元
|
| 2017-03-16 |
股东大会：
将于2017-04-27召开股东大会
会议内容 ▼▲
- 1.To receive the Company’s Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2016.
2.To confirm the first interim dividend of US$0.90 (68.7 pence, SEK 7.81) per ordinary share and to confirm as the final dividend for 2016 the second interim dividend of US$1.90 (150.2 pence, SEK 16.57) per ordinary share.
3.To appoint PricewaterhouseCoopers LLP as Auditor of the Company to hold office from the end of the AGM to the end of the next meeting at which accounts are laid before the Company.
4.To authorise the Directors to agree the remuneration of the Auditor.
5.To elect or re-elect the following Directors of the Company with effect from the end of the AGM as separate resolutions:
A separate vote will be taken in respect of the election or re-election of each Director. In accordance with Article 66 of the Company’s Articles of Association, all of the Directors will retire at the AGM and may present themselves for re-election.
6.To approve the annual statement of the Chairman of the Remuneration Committee and the Annual Report on Remuneration for the year ended 31 December 2016, as set out on pages 103 to 121 of the Annual Report, in accordance with section 439 of the Companies Act 2006.
7.To approve the Directors’ Remuneration Policy, as set out on pages 122 to 132 of the Annual Report in accordance with section 439A of the Companies Act 2006, to take effect from 27 April 2017.
8.That the Company and any company which is or becomes a subsidiary of the Company during the period to which this resolution relates be generally authorised to:
(a)make donations to political parties and/or independent election candidates;
(b)make donations to political organisations other than political parties;
(c)incur political expenditure
9.That:
(a)the Directors be generally and unconditionally authorised pursuant to section 551 of the Companies Act 2006 to:
(i)allot shares in the Company, and to grant rights to subscribe for or to convert any security into shares in the Company:
(A)up to an aggregate nominal amount of US$105,440,415;
(B)comprising equity securities (as defined in the Companies Act 2006) up to an aggregate nominal amount of US$210,880,831 (including within such limit any shares issued or rights granted under paragraph (A) above) in connection with an offer by way of a rights issue:
(I)to holders of ordinary shares in proportion (as nearly as may be practicable) to their existing holdings;
(II)to people who are holders of other equity securities if this is required by the rights of those securities or, if the Directors consider it necessary, as permitted by the rights of those securities;
(ii)make an offer or agreement which would or might require shares to be allotted, or rights to subscribe for or convert any security into shares to be granted, after expiry of this authority and the Directors may allot shares and grant rights in pursuance of that offer or agreement as if this authority had not expired;
(b)subject to paragraph (c) below, all existing authorities given to the Directors pursuant to section 551 of the Companies Act 2006 be revoked by this resolution;
(c)paragraph (b) above shall be without prejudice to the continuing authority of the Directors to allot shares, or grant rights to subscribe for or convert any security into shares, pursuant to an offer or agreement made by the Company before the expiry of the authority pursuant to which such offer or agreement was made.
10.That subject to the passing of Resolution 9 as set out in the Notice of AGM of the Company convened for 27 April 2017 and in place of the power given to them pursuant to the special resolution of the Company passed on 29 April 2016, the directors be generally empowered pursuant to section 570 and section 573 of the Companies Act 2006 to allot equity securities (as defined in the Companies Act 2006) for cash, pursuant to the authority conferred by Resolution 9 in the Notice of AGM as if section 561(1) of the Act did not apply to the allotment.
11.That the Company be unconditionally and generally authorised to make market purchases (within the meaning of section 693(4) of the Companies Act 2006) of its ordinary shares of US$0.25 each in the capital of the Company provided that:
(a)the maximum number of ordinary shares which may be purchased is 126,541,153;
(b)the minimum price (exclusive of expenses) which may be paid for each ordinary share is US$0.25;
(c)the maximum price (exclusive of expenses) which may be paid for each ordinary share is the higher of:
(i)an amount equal to 105% of the average of the middle market quotations for an ordinary share of the Company as derived from the London Stock Exchange Daily Official List for the five business days immediately preceding the day on which the ordinary share is contracted to be purchased;
(ii)an amount equal to the higher of the price of the last independent trade of an ordinary share and the highest current independent bid for an ordinary share as derived from the London Stock Exchange trading service SETS.
12.That a general meeting other than an Annual General Meeting may be called on not less than 14 clear days’ notice.
|
| 2017-03-16 |
股东大会：
将于2017-04-27召开股东大会
会议内容 ▼▲
- 1.To receive the Company’s Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2016.
2.To confirm the first interim dividend of US$0.90 (68.7 pence, SEK 7.81) per ordinary share and to confirm as the final dividend for 2016 the second interim dividend of US$1.90 (150.2 pence, SEK 16.57) per ordinary share.
3.To appoint PricewaterhouseCoopers LLP as Auditor of the Company to hold office from the end of the AGM to the end of the next meeting at which accounts are laid before the Company.
4.To authorise the Directors to agree the remuneration of the Auditor.
5.To elect or re-elect the following Directors of the Company with effect from the end of the AGM as separate resolutions:
A separate vote will be taken in respect of the election or re-election of each Director. In accordance with Article 66 of the Company’s Articles of Association, all of the Directors will retire at the AGM and may present themselves for re-election.
6.To approve the annual statement of the Chairman of the Remuneration Committee and the Annual Report on Remuneration for the year ended 31 December 2016, as set out on pages 103 to 121 of the Annual Report, in accordance with section 439 of the Companies Act 2006.
7.To approve the Directors’ Remuneration Policy, as set out on pages 122 to 132 of the Annual Report in accordance with section 439A of the Companies Act 2006, to take effect from 27 April 2017.
8.That the Company and any company which is or becomes a subsidiary of the Company during the period to which this resolution relates be generally authorised to:
(a)make donations to political parties and/or independent election candidates;
(b)make donations to political organisations other than political parties;
(c)incur political expenditure
9.That:
(a)the Directors be generally and unconditionally authorised pursuant to section 551 of the Companies Act 2006 to:
(i)allot shares in the Company, and to grant rights to subscribe for or to convert any security into shares in the Company:
(A)up to an aggregate nominal amount of US$105,440,415;
(B)comprising equity securities (as defined in the Companies Act 2006) up to an aggregate nominal amount of US$210,880,831 (including within such limit any shares issued or rights granted under paragraph (A) above) in connection with an offer by way of a rights issue:
(I)to holders of ordinary shares in proportion (as nearly as may be practicable) to their existing holdings;
(II)to people who are holders of other equity securities if this is required by the rights of those securities or, if the Directors consider it necessary, as permitted by the rights of those securities;
(ii)make an offer or agreement which would or might require shares to be allotted, or rights to subscribe for or convert any security into shares to be granted, after expiry of this authority and the Directors may allot shares and grant rights in pursuance of that offer or agreement as if this authority had not expired;
(b)subject to paragraph (c) below, all existing authorities given to the Directors pursuant to section 551 of the Companies Act 2006 be revoked by this resolution;
(c)paragraph (b) above shall be without prejudice to the continuing authority of the Directors to allot shares, or grant rights to subscribe for or convert any security into shares, pursuant to an offer or agreement made by the Company before the expiry of the authority pursuant to which such offer or agreement was made.
10.That subject to the passing of Resolution 9 as set out in the Notice of AGM of the Company convened for 27 April 2017 and in place of the power given to them pursuant to the special resolution of the Company passed on 29 April 2016, the directors be generally empowered pursuant to section 570 and section 573 of the Companies Act 2006 to allot equity securities (as defined in the Companies Act 2006) for cash, pursuant to the authority conferred by Resolution 9 in the Notice of AGM as if section 561(1) of the Act did not apply to the allotment.
11.That the Company be unconditionally and generally authorised to make market purchases (within the meaning of section 693(4) of the Companies Act 2006) of its ordinary shares of US$0.25 each in the capital of the Company provided that:
(a)the maximum number of ordinary shares which may be purchased is 126,541,153;
(b)the minimum price (exclusive of expenses) which may be paid for each ordinary share is US$0.25;
(c)the maximum price (exclusive of expenses) which may be paid for each ordinary share is the higher of:
(i)an amount equal to 105% of the average of the middle market quotations for an ordinary share of the Company as derived from the London Stock Exchange Daily Official List for the five business days immediately preceding the day on which the ordinary share is contracted to be purchased;
(ii)an amount equal to the higher of the price of the last independent trade of an ordinary share and the highest current independent bid for an ordinary share as derived from the London Stock Exchange trading service SETS.
12.That a general meeting other than an Annual General Meeting may be called on not less than 14 clear days’ notice.
|
| 2017-03-16 |
股东大会：
将于2017-04-27召开股东大会
会议内容 ▼▲
- 1.To receive the Company’s Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2016.
2.To confirm the first interim dividend of US$0.90 (68.7 pence, SEK 7.81) per ordinary share and to confirm as the final dividend for 2016 the second interim dividend of US$1.90 (150.2 pence, SEK 16.57) per ordinary share.
3.To appoint PricewaterhouseCoopers LLP as Auditor of the Company to hold office from the end of the AGM to the end of the next meeting at which accounts are laid before the Company.
4.To authorise the Directors to agree the remuneration of the Auditor.
5.To elect or re-elect the following Directors of the Company with effect from the end of the AGM as separate resolutions:
A separate vote will be taken in respect of the election or re-election of each Director. In accordance with Article 66 of the Company’s Articles of Association, all of the Directors will retire at the AGM and may present themselves for re-election.
6.To approve the annual statement of the Chairman of the Remuneration Committee and the Annual Report on Remuneration for the year ended 31 December 2016, as set out on pages 103 to 121 of the Annual Report, in accordance with section 439 of the Companies Act 2006.
7.To approve the Directors’ Remuneration Policy, as set out on pages 122 to 132 of the Annual Report in accordance with section 439A of the Companies Act 2006, to take effect from 27 April 2017.
8.That the Company and any company which is or becomes a subsidiary of the Company during the period to which this resolution relates be generally authorised to:
(a)make donations to political parties and/or independent election candidates;
(b)make donations to political organisations other than political parties;
(c)incur political expenditure
9.That:
(a)the Directors be generally and unconditionally authorised pursuant to section 551 of the Companies Act 2006 to:
(i)allot shares in the Company, and to grant rights to subscribe for or to convert any security into shares in the Company:
(A)up to an aggregate nominal amount of US$105,440,415;
(B)comprising equity securities (as defined in the Companies Act 2006) up to an aggregate nominal amount of US$210,880,831 (including within such limit any shares issued or rights granted under paragraph (A) above) in connection with an offer by way of a rights issue:
(I)to holders of ordinary shares in proportion (as nearly as may be practicable) to their existing holdings;
(II)to people who are holders of other equity securities if this is required by the rights of those securities or, if the Directors consider it necessary, as permitted by the rights of those securities;
(ii)make an offer or agreement which would or might require shares to be allotted, or rights to subscribe for or convert any security into shares to be granted, after expiry of this authority and the Directors may allot shares and grant rights in pursuance of that offer or agreement as if this authority had not expired;
(b)subject to paragraph (c) below, all existing authorities given to the Directors pursuant to section 551 of the Companies Act 2006 be revoked by this resolution;
(c)paragraph (b) above shall be without prejudice to the continuing authority of the Directors to allot shares, or grant rights to subscribe for or convert any security into shares, pursuant to an offer or agreement made by the Company before the expiry of the authority pursuant to which such offer or agreement was made.
10.That subject to the passing of Resolution 9 as set out in the Notice of AGM of the Company convened for 27 April 2017 and in place of the power given to them pursuant to the special resolution of the Company passed on 29 April 2016, the directors be generally empowered pursuant to section 570 and section 573 of the Companies Act 2006 to allot equity securities (as defined in the Companies Act 2006) for cash, pursuant to the authority conferred by Resolution 9 in the Notice of AGM as if section 561(1) of the Act did not apply to the allotment.
11.That the Company be unconditionally and generally authorised to make market purchases (within the meaning of section 693(4) of the Companies Act 2006) of its ordinary shares of US$0.25 each in the capital of the Company provided that:
(a)the maximum number of ordinary shares which may be purchased is 126,541,153;
(b)the minimum price (exclusive of expenses) which may be paid for each ordinary share is US$0.25;
(c)the maximum price (exclusive of expenses) which may be paid for each ordinary share is the higher of:
(i)an amount equal to 105% of the average of the middle market quotations for an ordinary share of the Company as derived from the London Stock Exchange Daily Official List for the five business days immediately preceding the day on which the ordinary share is contracted to be purchased;
(ii)an amount equal to the higher of the price of the last independent trade of an ordinary share and the highest current independent bid for an ordinary share as derived from the London Stock Exchange trading service SETS.
12.That a general meeting other than an Annual General Meeting may be called on not less than 14 clear days’ notice.
|
| 2017-02-02 |
除权日：
美东时间 2017-02-15 每股派息0.95美元
|
| 2016-07-29 |
除权日：
美东时间 2016-08-10 每股派息0.44美元
|
| 2016-03-18 |
股东大会：
将于2016-04-29召开股东大会
会议内容 ▼▲
- Ordinary resolutions
1. To receive the Company’s Accounts and the Reports of the Directors and Auditor for the year ended 31 December 2015.
2. To confirm the first interim dividend of US$0.90 (57.5 pence, SEK 7.71) per ordinary share and to confirm as the final dividend for 2015 the second interim dividend of US$1.90 (131.0 pence, SEK 16.26) per ordinary share.
3. To re-appoint KPMG LLP, London as Auditor of the Company.
4. To authorise the Directors to agree the remuneration of the Auditor.
5. To re-elect Directors of the Company with effect from the end of the AGM as separate resolutions
6. To approve the annual statement of the Chairman of the Remuneration Committee and the Annual Report on Remuneration for the year ended 31 December 2015, as set out on pages 103 to 121 of the Annual Report, in accordance with section 439 of the Companies Act 2006.
7. That the Company and any company which is or becomes a subsidiary of the Company during the period to which this resolution relates be and are hereby authorised to:
(a) make donations to political parties or independent election candidates;
(b) make donations to political organisations other than political parties;
(c) incur political expenditure,
during the period commencing on the date of this resolution and ending on the date of the Company’s next AGM, provided that any such donations and expenditure made by the Company or by any subsidiary shall not exceed US$250,000 per company and together with those made by any subsidiary and the Company shall not exceed in aggregate US$250,000. Any terms used in this resolution which are defined in Part 14 of the Companies Act 2006 shall bear the same meaning for the purposes of this resolution.
8. That:
(a) the directors be generally and unconditionally authorised pursuant to section 551 of the Companies Act 2006 to:
(i) allot shares in the Company, and to grant rights to subscribe for or to convert any security into shares in the Company:
(A) up to an aggregate nominal amount of US$105,342,226
(B) comprising equity securities (as defined in the Companies Act 2006) up to an aggregate nominal amount of US$210,684,452 (including within such limit any shares issued or rights granted under paragraph (A) above) in connection with an offer by way of a rights issue:
(I) to holders of ordinary shares in proportion (as nearly as may be practicable) to their existing holdings;
(II) to people who are holders of other equity securities if this is required by the rights of those securities or, if the directors consider it necessary, as permitted by the rights of those securities;
and so that the directors may impose any limits or restrictions and make any arrangements which they consider necessary or appropriate to deal with treasury shares, fractional entitlements, record dates, legal, regulatory or practical problems in, or under the laws of, any territory or any other matter,
for a period expiring (unless previously renewed, varied or revoked by the Company in general meeting) at the end of the next AGM of the Company after the date on which this resolution is passed (or, if earlier, at the close of business on 29 July 2017)
(ii) make an offer or agreement which would or might require shares to be allotted, or rights to subscribe for or convert any security into shares to be granted, after expiry of this authority and the directors may allot shares and grant rights in pursuance of that offer or agreement as if this authority had not expired;
(b) subject to paragraph (c) below, all existing authorities given to the directors pursuant to section 551 of the Companies Act 2006 be revoked by this resolution
(c) paragraph (b) above shall be without prejudice to the continuing authority of the directors to allot shares, or grant rights to subscribe for or convert any security into shares, pursuant to an offer or agreement made by the Company before the expiry of the authority pursuant to which such offer or agreement was made.
Special resolutions
9. That subject to the passing of Resolution 8 as set out in the Notice of AGM of the Company convened for 29 April 2016 and in place of the power given to them pursuant to the special resolution of the Company passed on 24 April 2015, the directors be generally empowered pursuant to section 570 and section 573 of the Companies Act 2006 to allot equity securities (as defined in the Companies Act 2006) for cash, pursuant to the authority conferred by Resolution 8 in the Notice of AGM as if section 561(1) of the Act did not apply to the allotment.
10. That the Company be and is hereby unconditionally and generally authorised to make market purchases (within the meaning of section 693(4) of the Companies Act 2006) of its ordinary shares of US$0.25 each in the capital of the Company provided that:
(a) the maximum number of ordinary shares which may be purchased is 126,423,313;
(b) the minimum price (exclusive of expenses) which may be paid for each ordinary share is US$0.25;
(c) the maximum price (exclusive of expenses) which may be paid for each ordinary share is the higher of:
(i) an amount equal to 105% of the average of the middle market quotations for an ordinary share of the Company as derived from the London Stock Exchange Daily Official List for the five business days immediately preceding the day on which the ordinary share is contracted to be purchased;
(ii) an amount equal to the higher of the price of the last independent trade of an ordinary share and the highest current independent bid for an ordinary share as derived from the London Stock Exchange Trading System.
This authority shall expire at the conclusion of the Annual General Meeting of the Company held in 2017 or, if earlier, at the close of business on 29 July 2017 (except in relation to the purchase of shares the contract for which was concluded before the expiry of such authority and which might be executed wholly or partly after such expiry).
11. That a general meeting other than an AGM may be called on not less than 14 clear days’ notice.
|
| 2016-03-18 |
股东大会：
将于2016-04-29召开股东大会
会议内容 ▼▲
- Ordinary resolutions
1. To receive the Company’s Accounts and the Reports of the Directors and Auditor for the year ended 31 December 2015.
2. To confirm the first interim dividend of US$0.90 (57.5 pence, SEK 7.71) per ordinary share and to confirm as the final dividend for 2015 the second interim dividend of US$1.90 (131.0 pence, SEK 16.26) per ordinary share.
3. To re-appoint KPMG LLP, London as Auditor of the Company.
4. To authorise the Directors to agree the remuneration of the Auditor.
5. To re-elect Directors of the Company with effect from the end of the AGM as separate resolutions
6. To approve the annual statement of the Chairman of the Remuneration Committee and the Annual Report on Remuneration for the year ended 31 December 2015, as set out on pages 103 to 121 of the Annual Report, in accordance with section 439 of the Companies Act 2006.
7. That the Company and any company which is or becomes a subsidiary of the Company during the period to which this resolution relates be and are hereby authorised to:
(a) make donations to political parties or independent election candidates;
(b) make donations to political organisations other than political parties;
(c) incur political expenditure,
during the period commencing on the date of this resolution and ending on the date of the Company’s next AGM, provided that any such donations and expenditure made by the Company or by any subsidiary shall not exceed US$250,000 per company and together with those made by any subsidiary and the Company shall not exceed in aggregate US$250,000. Any terms used in this resolution which are defined in Part 14 of the Companies Act 2006 shall bear the same meaning for the purposes of this resolution.
8. That:
(a) the directors be generally and unconditionally authorised pursuant to section 551 of the Companies Act 2006 to:
(i) allot shares in the Company, and to grant rights to subscribe for or to convert any security into shares in the Company:
(A) up to an aggregate nominal amount of US$105,342,226
(B) comprising equity securities (as defined in the Companies Act 2006) up to an aggregate nominal amount of US$210,684,452 (including within such limit any shares issued or rights granted under paragraph (A) above) in connection with an offer by way of a rights issue:
(I) to holders of ordinary shares in proportion (as nearly as may be practicable) to their existing holdings;
(II) to people who are holders of other equity securities if this is required by the rights of those securities or, if the directors consider it necessary, as permitted by the rights of those securities;
and so that the directors may impose any limits or restrictions and make any arrangements which they consider necessary or appropriate to deal with treasury shares, fractional entitlements, record dates, legal, regulatory or practical problems in, or under the laws of, any territory or any other matter,
for a period expiring (unless previously renewed, varied or revoked by the Company in general meeting) at the end of the next AGM of the Company after the date on which this resolution is passed (or, if earlier, at the close of business on 29 July 2017)
(ii) make an offer or agreement which would or might require shares to be allotted, or rights to subscribe for or convert any security into shares to be granted, after expiry of this authority and the directors may allot shares and grant rights in pursuance of that offer or agreement as if this authority had not expired;
(b) subject to paragraph (c) below, all existing authorities given to the directors pursuant to section 551 of the Companies Act 2006 be revoked by this resolution
(c) paragraph (b) above shall be without prejudice to the continuing authority of the directors to allot shares, or grant rights to subscribe for or convert any security into shares, pursuant to an offer or agreement made by the Company before the expiry of the authority pursuant to which such offer or agreement was made.
Special resolutions
9. That subject to the passing of Resolution 8 as set out in the Notice of AGM of the Company convened for 29 April 2016 and in place of the power given to them pursuant to the special resolution of the Company passed on 24 April 2015, the directors be generally empowered pursuant to section 570 and section 573 of the Companies Act 2006 to allot equity securities (as defined in the Companies Act 2006) for cash, pursuant to the authority conferred by Resolution 8 in the Notice of AGM as if section 561(1) of the Act did not apply to the allotment.
10. That the Company be and is hereby unconditionally and generally authorised to make market purchases (within the meaning of section 693(4) of the Companies Act 2006) of its ordinary shares of US$0.25 each in the capital of the Company provided that:
(a) the maximum number of ordinary shares which may be purchased is 126,423,313;
(b) the minimum price (exclusive of expenses) which may be paid for each ordinary share is US$0.25;
(c) the maximum price (exclusive of expenses) which may be paid for each ordinary share is the higher of:
(i) an amount equal to 105% of the average of the middle market quotations for an ordinary share of the Company as derived from the London Stock Exchange Daily Official List for the five business days immediately preceding the day on which the ordinary share is contracted to be purchased;
(ii) an amount equal to the higher of the price of the last independent trade of an ordinary share and the highest current independent bid for an ordinary share as derived from the London Stock Exchange Trading System.
This authority shall expire at the conclusion of the Annual General Meeting of the Company held in 2017 or, if earlier, at the close of business on 29 July 2017 (except in relation to the purchase of shares the contract for which was concluded before the expiry of such authority and which might be executed wholly or partly after such expiry).
11. That a general meeting other than an AGM may be called on not less than 14 clear days’ notice.
|
| 2016-03-18 |
股东大会：
将于2016-04-29召开股东大会
会议内容 ▼▲
- Ordinary resolutions
1. To receive the Company’s Accounts and the Reports of the Directors and Auditor for the year ended 31 December 2015.
2. To confirm the first interim dividend of US$0.90 (57.5 pence, SEK 7.71) per ordinary share and to confirm as the final dividend for 2015 the second interim dividend of US$1.90 (131.0 pence, SEK 16.26) per ordinary share.
3. To re-appoint KPMG LLP, London as Auditor of the Company.
4. To authorise the Directors to agree the remuneration of the Auditor.
5. To re-elect Directors of the Company with effect from the end of the AGM as separate resolutions
6. To approve the annual statement of the Chairman of the Remuneration Committee and the Annual Report on Remuneration for the year ended 31 December 2015, as set out on pages 103 to 121 of the Annual Report, in accordance with section 439 of the Companies Act 2006.
7. That the Company and any company which is or becomes a subsidiary of the Company during the period to which this resolution relates be and are hereby authorised to:
(a) make donations to political parties or independent election candidates;
(b) make donations to political organisations other than political parties;
(c) incur political expenditure,
during the period commencing on the date of this resolution and ending on the date of the Company’s next AGM, provided that any such donations and expenditure made by the Company or by any subsidiary shall not exceed US$250,000 per company and together with those made by any subsidiary and the Company shall not exceed in aggregate US$250,000. Any terms used in this resolution which are defined in Part 14 of the Companies Act 2006 shall bear the same meaning for the purposes of this resolution.
8. That:
(a) the directors be generally and unconditionally authorised pursuant to section 551 of the Companies Act 2006 to:
(i) allot shares in the Company, and to grant rights to subscribe for or to convert any security into shares in the Company:
(A) up to an aggregate nominal amount of US$105,342,226
(B) comprising equity securities (as defined in the Companies Act 2006) up to an aggregate nominal amount of US$210,684,452 (including within such limit any shares issued or rights granted under paragraph (A) above) in connection with an offer by way of a rights issue:
(I) to holders of ordinary shares in proportion (as nearly as may be practicable) to their existing holdings;
(II) to people who are holders of other equity securities if this is required by the rights of those securities or, if the directors consider it necessary, as permitted by the rights of those securities;
and so that the directors may impose any limits or restrictions and make any arrangements which they consider necessary or appropriate to deal with treasury shares, fractional entitlements, record dates, legal, regulatory or practical problems in, or under the laws of, any territory or any other matter,
for a period expiring (unless previously renewed, varied or revoked by the Company in general meeting) at the end of the next AGM of the Company after the date on which this resolution is passed (or, if earlier, at the close of business on 29 July 2017)
(ii) make an offer or agreement which would or might require shares to be allotted, or rights to subscribe for or convert any security into shares to be granted, after expiry of this authority and the directors may allot shares and grant rights in pursuance of that offer or agreement as if this authority had not expired;
(b) subject to paragraph (c) below, all existing authorities given to the directors pursuant to section 551 of the Companies Act 2006 be revoked by this resolution
(c) paragraph (b) above shall be without prejudice to the continuing authority of the directors to allot shares, or grant rights to subscribe for or convert any security into shares, pursuant to an offer or agreement made by the Company before the expiry of the authority pursuant to which such offer or agreement was made.
Special resolutions
9. That subject to the passing of Resolution 8 as set out in the Notice of AGM of the Company convened for 29 April 2016 and in place of the power given to them pursuant to the special resolution of the Company passed on 24 April 2015, the directors be generally empowered pursuant to section 570 and section 573 of the Companies Act 2006 to allot equity securities (as defined in the Companies Act 2006) for cash, pursuant to the authority conferred by Resolution 8 in the Notice of AGM as if section 561(1) of the Act did not apply to the allotment.
10. That the Company be and is hereby unconditionally and generally authorised to make market purchases (within the meaning of section 693(4) of the Companies Act 2006) of its ordinary shares of US$0.25 each in the capital of the Company provided that:
(a) the maximum number of ordinary shares which may be purchased is 126,423,313;
(b) the minimum price (exclusive of expenses) which may be paid for each ordinary share is US$0.25;
(c) the maximum price (exclusive of expenses) which may be paid for each ordinary share is the higher of:
(i) an amount equal to 105% of the average of the middle market quotations for an ordinary share of the Company as derived from the London Stock Exchange Daily Official List for the five business days immediately preceding the day on which the ordinary share is contracted to be purchased;
(ii) an amount equal to the higher of the price of the last independent trade of an ordinary share and the highest current independent bid for an ordinary share as derived from the London Stock Exchange Trading System.
This authority shall expire at the conclusion of the Annual General Meeting of the Company held in 2017 or, if earlier, at the close of business on 29 July 2017 (except in relation to the purchase of shares the contract for which was concluded before the expiry of such authority and which might be executed wholly or partly after such expiry).
11. That a general meeting other than an AGM may be called on not less than 14 clear days’ notice.
|
| 2016-02-25 |
除权日：
美东时间 2016-02-17 每股派息0.93美元
|
| 2015-07-30 |
除权日：
美东时间 2015-08-12 每股派息0.45美元
|
| 2015-07-27 |
详情>>
拆分方案：
每1.0000股拆分成2.0000股
|
| 2015-02-09 |
除权日：
美东时间 2015-02-18 每股派息1.90美元
|
| 2014-07-31 |
除权日：
美东时间 2014-08-13 每股派息0.90美元
|
| 2014-02-07 |
除权日：
美东时间 2014-02-19 每股派息1.90美元
|
| 2013-08-01 |
除权日：
美东时间 2013-08-14 每股派息0.90美元
|
| 2013-01-31 |
除权日：
美东时间 2013-02-13 每股派息1.90美元
|
| 2012-07-26 |
除权日：
美东时间 2012-08-08 每股派息0.90美元
|
| 2012-02-02 |
除权日：
美东时间 2012-02-15 每股派息1.95美元
|
| 2011-07-28 |
除权日：
美东时间 2011-08-04 每股派息0.85美元
|
| 2011-01-27 |
除权日：
美东时间 2011-02-02 每股派息1.85美元
|
| 2010-07-29 |
除权日：
美东时间 2010-08-04 每股派息0.70美元
|